Researchers report on a previously unknown relationship between stem cell potency and the metabolic rate of their mitochondria ľa cell's energy makers. Stem cells with more active mitochondria also have a greater capacity to differentiate and are more likely to form tumors.
These findings, appearing this week in JBC, could lead to methods of enriching the best stem cells from a population for therapeutic use and may provide some insights into the role of stem cells in cancer.
This study, conducted by Toren Finkel and colleagues at the National Heart, Lung and Blood Institute (NHBLI), sorted mouse embryonic stem cells by their mitochondrial potential (the amount of voltage going across mitochondrial membranes, similar to how nerve activity is measured) and found that both visually and in the expression of key stem cell markers, low and high metabolism stem cells were indistinguishable.
Yet, when transplanted into mice, these two types of cells had contrasting properties, as cells with lower metabolic rates were more efficient at differentiating into other cell types while the highly metabolic cells were more prone to keep dividing and form teratomas, tumors characterized by having various tissue types mixed together.
The potential of stem cells to form teratomas remains a big obstacle in their clinical use, but these results may have at least uncovered the mechanism behind it. In fact, when Finkel and colleagues administered the mitochondrial inhibitor rapamycin to high metabolism stem cells, their teratoma capacity decreased significantly.
While this work was done with mouse cells, the researchers believe a similar relationship holds true in human stem cells. Thus, developing methods to remove highly metabolic stem cells from a population could improve their safety.
From the JBC article: "Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells" by Stefan Schieke, Mingchao Ma, Liu Cao, J. Phillip McCoy Jr., Chengyu Liu, Nancy Hensel, A. John Barrett, Manfred Boehm and Toren Finkel
Corresponding Authors: Toren Finkel or Manfred Boehm, Translational Medicine Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD; E-Mail: firstname.lastname@example.org or email@example.com
The American Society for Biochemistry and Molecular Biology is a nonprofit scientific and educational organization with over 11,900 members in the United States and internationally. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, nonprofit research institutions and industry. The Society's student members attend undergraduate or graduate institutions.
Founded in 1906, the Society is based in Bethesda, Maryland, on the campus of the Federation of American Societies for Experimental Biology. The Society's purpose is to advance the science of biochemistry and molecular biology through publication of the Journal of Biological Chemistry, the Journal of Lipid Research, and Molecular and Cellular Proteomics, organization of scientific meetings, advocacy for funding of basic research and education, support of science education at all levels, and promoting the diversity of individuals entering the scientific work force.
For more information about ASBMB, see the Society's Web site at www.asbmb.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.